<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00551642</url>
  </required_header>
  <id_info>
    <org_study_id>INOT27</org_study_id>
    <secondary_id>EUNO, EU Preemie</secondary_id>
    <nct_id>NCT00551642</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Nitric Oxide for Inhalation on Chronic Lung Disease in Premature Babies</brief_title>
  <official_title>The Effects of Nitric Oxide for Inhalation on the Development of Chronic Lung Disease in Pre-term Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mallinckrodt</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mallinckrodt</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and efficacy of inhaled nitric oxide to
      reduce the risk of chronic lung disease in pre-term infants with respiratory distress, and to
      assess the long-term effects of the therapy on the development of these children over 7 years
      of clinical follow-up.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although the effects of inhaled Nitric Oxide on pulmonary vascular tone are well-described
      and relevant to term infants with persistent pulmonary hypertension, the pathophysiology of
      respiratory failure in preterm infants may be quite different. Chronic lung disease (CLD)
      represents the final pathway of a heterogeneous group of pulmonary disorders of infancy that
      usually start in the neonatal period. CLD most commonly occurs in preterm (&lt;30 weeks of
      gestational age (GA) infants with birth weights less than 1,500 g, and especially in those
      very preterm (&lt;26 wks GA) with birth weights less than 1,000 g, and who have been treated for
      respiratory distress syndrome (RDS).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival Without Bronchopulmonary Dysplasia (BPD) in Preterm Infants With Respiratory Distress</measure>
    <time_frame>36 weeks gestational age</time_frame>
    <description>The primary outcome was determined by assessment of survival and incidence of BPD,which was defined by the need for supplemental oxygen at 36 weeks gestational age (GA); an infant who was alive without BPD at 36 weeks GA was counted as success; an infant who died or had BPD at 36 weeks GA was counted as a failure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>36 Weeks GA</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vital Signs</measure>
    <time_frame>Study Duration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial Oxygen Saturation by Pulse Oximetry</measure>
    <time_frame>Study Duration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Study Duration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Methemoglobin Level</measure>
    <time_frame>Baseline, then 24 hours, 2-6 days, Day 7 and Day 14 of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">800</enrollment>
  <condition>Lung Disease</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>24+0-25+6 days weeks gestational age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>26+0 - 28+6 days weeks Gestational Age</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitric Oxide for inhalation</intervention_name>
    <description>inhaled nitric oxide given at 5 parts per million (ppm) for 7-21 days</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <other_name>INOmax®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitrogen</intervention_name>
    <description>nitrogen gas given at 5ppm for 7-21 days</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Inborn preterm infants 24+0 weeks-28+6 days weeks gestational age (defined by first
             trimester ultrasound or if not available based on the last menstrual period) who
             requires the use of surfactant within 24 hours of birth (either prophylactically, or
             for signs of developing respiratory distress), or who requires the use of continuous
             positive airway pressure (CPAP) (fraction of inspired oxygen concentration (FiO2) ≥
             0.30 on a mean airway pressure ≥ 4cm water (H2O)) within 24 hours of birth in order to
             maintain an oxygen saturation (SpO2) ≥ 85%.

          -  Informed consent of the guardian.

        Exclusion Criteria:

          -  Outborn infants.

          -  Infants ≥ 29 weeks gestational age.

          -  Infants requiring FiO2 &gt;0.5 to maintain SpO2 &gt;85%, on a sufficient mean airway
             pressure (e.g., &gt; 8 cm H2O on controlled mechanical ventilation (CMV)) in order to
             achieve adequate chest inflation (8-9 ribs on Chest X-ray) two hours after the proper
             administration of exogenous surfactant.

          -  Any suspected congenital heart disease other than patent ductus arteriosus or atrial
             septal defect.

          -  Any infant with severe bleeding or coagulation abnormalities at high-risk of
             diathesis, e.g., platelet &lt;50,000/mm³, fibrinogen &lt;0.5 g/L, other clotting factors
             &lt;10%.

          -  Any infant in whom a decision has been made not to provide full treatment, e.g.,
             chromosomal abnormalities, severe multiple abnormalities, severe birth asphyxia, etc.

          -  Use of another investigational drug or device before or during the active study
             period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>26 Hours</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Christophe Mercier</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Robert Debre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCL St. LUC</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Notre Dame</name>
      <address>
        <city>Charleroi</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique St. Vincent CHC</name>
      <address>
        <city>Rocourt</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oulun yliopsistollinen sairaala</name>
      <address>
        <city>Oulu</city>
        <zip>FI-90220</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal de Creteil</name>
      <address>
        <city>Creteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Mere-Enfant</name>
      <address>
        <city>Nantes Cedex 1</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Robert Debre</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Campus Charite Mitte</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69115</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Marburg</name>
      <address>
        <city>Marburg</city>
        <zip>35033</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Muenchen</name>
      <address>
        <city>Muenchen</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaeklinikum Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univeritaetsklinik Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Az. Osp. G. Salesi</name>
      <address>
        <city>Ancona</city>
        <zip>60123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedali Riuniti</name>
      <address>
        <city>Bergamo</city>
        <zip>24128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico S. Orsola</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Careggi</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Padova</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Gemelli</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beatrix Children's Hospital, University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sophia Kinderziekenhuis</name>
      <address>
        <city>Rotterdam</city>
        <zip>3000 CB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Cruces</name>
      <address>
        <city>Barakaldo (Vizcaya)</city>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Gregorio Mar</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosspital Univeritario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Canarias</name>
      <address>
        <city>Santa Cruz de Tenerife</city>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Astrid Lindgrens barnsjukjus, Karolinska Unviersritets sjukhuset-Solna</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akademiska Sjukhuset</name>
      <address>
        <city>Uppsala</city>
        <zip>SE-751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meedway Mariton Hospital</name>
      <address>
        <city>Kent</city>
        <zip>ME7 5NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leicester Royal Infirmary</name>
      <address>
        <city>Leicester</city>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kings College</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2007</study_first_submitted>
  <study_first_submitted_qc>October 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2007</study_first_posted>
  <results_first_submitted>September 3, 2010</results_first_submitted>
  <results_first_submitted_qc>September 30, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 18, 2010</results_first_posted>
  <last_update_submitted>November 3, 2016</last_update_submitted>
  <last_update_submitted_qc>November 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Preemie, Inhaled Nitric Oxide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitric Oxide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Thirty-five Medical Centers participated and enrolled a total of 800 subjects (Intent to treat population). The study allowed for a 2 year recruitment and intervention period followed by 7 years of clinical follow up.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Inhaled Nitric Oxide (NO)</title>
          <description>Inhaled NO administered by nasal continuous positve airway pressure, nasal cannula or face mask at 5 parts per million (ppm) for a maximum of 21 days</description>
        </group>
        <group group_id="P2">
          <title>Placebo (Nitrogen)</title>
          <description>Placebo Nitrogen gas administered by nasal continuous positve airway pressure, nasal cannula or face mask at 5 parts per million for a maximum of 21 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="399"/>
                <participants group_id="P2" count="401"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="338"/>
                <participants group_id="P2" count="338"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="63"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Delivery device failure</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inclusion/Exclusion criteria</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Inhaled Nitric Oxide (NO)</title>
          <description>Inhaled NO administered by nasal continuous positve airway pressure, nasal cannula or face mask at 5 parts per million (ppm) for a maximum of 21 days</description>
        </group>
        <group group_id="B2">
          <title>Placebo (Nitrogen)</title>
          <description>Placebo Nitrogen gas administered by nasal continuous positve airway pressure, nasal cannula or face mask at 5 parts per million for a maximum of 21 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="399"/>
            <count group_id="B2" value="401"/>
            <count group_id="B3" value="800"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="399"/>
                    <measurement group_id="B2" value="401"/>
                    <measurement group_id="B3" value="800"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.4" spread="1.3"/>
                    <measurement group_id="B2" value="26.6" spread="1.3"/>
                    <measurement group_id="B3" value="26.5" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="192"/>
                    <measurement group_id="B2" value="181"/>
                    <measurement group_id="B3" value="373"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="207"/>
                    <measurement group_id="B2" value="220"/>
                    <measurement group_id="B3" value="427"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Finland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="114"/>
                    <measurement group_id="B2" value="117"/>
                    <measurement group_id="B3" value="231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Survival Without Bronchopulmonary Dysplasia (BPD) in Preterm Infants With Respiratory Distress</title>
        <description>The primary outcome was determined by assessment of survival and incidence of BPD,which was defined by the need for supplemental oxygen at 36 weeks gestational age (GA); an infant who was alive without BPD at 36 weeks GA was counted as success; an infant who died or had BPD at 36 weeks GA was counted as a failure.</description>
        <time_frame>36 weeks gestational age</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Nitric Oxide (NO)</title>
            <description>Inhaled NO administered by nasal continuous positve airway pressure, nasal cannula or face mask at 5 parts per million (ppm) for a maximum of 21 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Nitrogen)</title>
            <description>Placebo Nitrogen gas administered by nasal continuous positve airway pressure, nasal cannula or face mask at 5 parts per million for a maximum of 21 days</description>
          </group>
        </group_list>
        <measure>
          <title>Survival Without Bronchopulmonary Dysplasia (BPD) in Preterm Infants With Respiratory Distress</title>
          <description>The primary outcome was determined by assessment of survival and incidence of BPD,which was defined by the need for supplemental oxygen at 36 weeks gestational age (GA); an infant who was alive without BPD at 36 weeks GA was counted as success; an infant who died or had BPD at 36 weeks GA was counted as a failure.</description>
          <units>participants alive without BPD</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="399"/>
                <count group_id="O2" value="401"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="258"/>
                    <measurement group_id="O2" value="262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Survival</title>
        <time_frame>36 Weeks GA</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vital Signs</title>
        <time_frame>Study Duration</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Arterial Oxygen Saturation by Pulse Oximetry</title>
        <time_frame>Study Duration</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events</title>
        <time_frame>Study Duration</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Methemoglobin Level</title>
        <time_frame>Baseline, then 24 hours, 2-6 days, Day 7 and Day 14 of treatment</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Inhaled Nitric Oxide (NO)</title>
          <description>Inhaled NO administered by nasal continuous positve airway pressure, nasal cannula or face mask at 5 parts per million (ppm) for a maximum of 21 days</description>
        </group>
        <group group_id="E2">
          <title>Placebo (Nitrogen)</title>
          <description>Placebo Nitrogen gas administered by nasal continuous positve airway pressure, nasal cannula or face mask at 5 parts per million for a maximum of 21 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="158" subjects_at_risk="399"/>
                <counts group_id="E2" subjects_affected="164" subjects_at_risk="401"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="401"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="401"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="401"/>
              </event>
              <event>
                <sub_title>Cardiac Tamponade</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="401"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary Failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="401"/>
              </event>
              <event>
                <sub_title>Supraventricular Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="401"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Patent Ductus Arteriosus</sub_title>
                <counts group_id="E1" events="59" subjects_affected="59" subjects_at_risk="399"/>
                <counts group_id="E2" events="46" subjects_affected="46" subjects_at_risk="401"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Intestinal Perforation</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="399"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="401"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="32" subjects_affected="32" subjects_at_risk="399"/>
                <counts group_id="E2" events="31" subjects_affected="31" subjects_at_risk="401"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhage Intracranial</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="49" subjects_affected="49" subjects_at_risk="399"/>
                <counts group_id="E2" events="41" subjects_affected="41" subjects_at_risk="401"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="399"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="401"/>
              </event>
              <event>
                <sub_title>Pulmonary Haemorrhage</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="399"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="401"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="380" subjects_at_risk="399"/>
                <counts group_id="E2" subjects_affected="365" subjects_at_risk="401"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="189" subjects_affected="189" subjects_at_risk="399"/>
                <counts group_id="E2" events="169" subjects_affected="169" subjects_at_risk="401"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Patent Ductus Arteriosus</sub_title>
                <counts group_id="E1" events="218" subjects_affected="218" subjects_at_risk="399"/>
                <counts group_id="E2" events="191" subjects_affected="191" subjects_at_risk="401"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Collapse of Lung</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="401"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Lawrence Hill</name_or_title>
      <organization>Mallinckrodt</organization>
      <phone>908-238-6370</phone>
      <email>lawrence.hill@mallinckrodt.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

